Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 22, 2011 
March 22, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , announced today that these select companies have been After the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. CAPGEMINI SA - UNSPONSOR ADR (OTC:CGEMY), POWERSHARES FTSE RAFI US 150 (NASDAQ:PRFZ), ARYX THERAPEUTICS INC (OTC:ARYX), CYTOCORE INC (OTCBB:CYOE). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
CAPGEMINI SA - UNSPONSOR ADR (OTC:CGEMY) - Cap Gemini S.A. provides consulting, technology, outsourcing, and local professional services. The company offers consultancy services in the areas of strategy and transformation; marketing, sales, and service; finance transformation; human resources consulting; supply chain management; and technology transformation. It also provides outsourcing services, including application outsourcing, business process outsourcing, infrastructure outsourcing, green information technology (IT), service management, and service desk services. In addition, the companys technology services comprise TechnoVision that provides information about the technological trends to plan and execute business strategies; application development and integration; IT transformation strategy and architecture; business intelligence; IT infrastructure and security; mobility transformation; and software and quality management testing. Further, it provides local professional services, which include application services, such as consulting and integration of management applications; technical infrastructure and information technology production services; and scientific engineering, technical and industrial IT, mechanics, and electronics in various industrial research and development projects; and onshore/offshore testing solutions, including managed testing services and TMap and TPI based services. The company serves aerospace and defense, automotive, consumer products, distribution and transportation, energy, utilities, chemicals, financial services, high tech, industrial products, life sciences, manufacturing, public sector, retail, telecom, media, and entertainment industries. It has operations in Africa, the Americas, the Asia Pacific, Europe, and the Middle East. Cap Gemini S.A. has a strategic alliance with Oracle Corp. to market and implement Oracle Revenue Management for Public. The company was founded in 1967 and is headquartered in Paris, France.There is a failure to deliver in shares of CGEMY
POWERSHARES FTSE RAFI US 150 (NASDAQ:PRFZ) - Powershares Exchange-Traded Fund Trust - Powershares Ftse Rafi Us 1500 Small-Mid PortfolioThere is a failure to deliver in shares of PRFZ
ARYX THERAPEUTICS INC (OTC:ARYX) - ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with commercialized drugs in the United States. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The companys other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics was incorporated in 1997 and is based in Fremont, California.There is a failure to deliver in shares of ARYX
CYTOCORE INC (OTCBB:CYOE) - Cytocore Inc. develops, manufactures, and sells an integrated family of products for the detection, diagnosis, and treatment of cancer under CytoCore Solutions trade name. The company offers its CytoCore Solutions products primarily for cervical cancer, and to address the sample collection, specimen preparation, and patient treatment and monitoring, as well as for specimen evaluation, including detection/screening and diagnosis related to specific cancers. Its cell collection devices include SoftPAP, a cell collection device for the collection of cervical cell samples that are used in the detection of cervical dysplasia, cancer, and HPV infections; and PadKit, a sample collection device that captures a sample to be evaluated to provide an assessment of the health of the female genital tract. The company s specimen preparation products comprise GluCyte, a cell preservative and methodology that provides a means for laboratories to transition from smears to LBPs; and stains and reagents for use in cervical cytology and other screening applications. Its specimen evaluation products include AIPS workstation to address the root causes of various ergonomic problems; AIPS Imager, a medical screening program to differentiate between patients who show no evidence of the target disease state and those who do; and OmniDROP, a communicator software that is provided as a software-as-a-service product for AIPS systems, as well as for laboratories, hospitals, and health maintenance organizations. In addition, the company develops a derivative of the SoftPAP cell collection device to apply a patch containing a therapeutic agent to the cervix. The company was formerly known as Molecular Diagnostics, Inc. and changed its name to Cytocore Inc. in 2006. The company is based in Chicago, Illinois.There is a failure to deliver in shares of CYOE
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,750,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
Contact: Thomas Ronk / CEO www.BUYINS.net (800) 715-9999 tom@buyins.net
- WOPRAI
- support@woprai.com